Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression.

Authors
Type
Published Article
Journal
Cancer Research
1538-7445
Publisher
American Association for Cancer Research
Publication Date
Volume
74
Issue
10
Pages
2803–2815
Identifiers
DOI: 10.1158/0008-5472.CAN-13-2732
PMID: 24686171
Source
Medline
License
Unknown

Abstract

Sphingosine kinase 2 (SK2) may have utility as a prognostic marker in inflammatory diseases such as cancer in which it has been rationalized as a candidate therapeutic target. Here, we show that SK2 has an oncogenic role in acute lymphoblastic leukemia (ALL) by influencing expression of MYC. Genetic ablation of SK2 impaired leukemia development in a mouse model of ALL and pharmacologic inhibition extended survival in mouse xenograft models of human disease. SK2 attenuation in both the settings reduced MYC expression in leukemic cells, with reduced levels of acetylated histone H3 within the MYC gene associated with reduced levels of MYC protein and expression of MYC-regulated genes. Our results demonstrated that SK2 regulates MYC, which has a pivotal role in hematologic malignancies, providing a preclinical proof of concept for this pathway as a broad-based therapeutic target in this setting.

Statistics

Seen <100 times